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Abstract
Background: Lung cancer is the leading cause of cancer deaths in the world. The most common type of lung
cancer is lung adenocarcinoma (AC). The genetic mechanisms of the early stages and lung AC progression steps
are poorly understood. There is currently no clinically applicable gene test for the early diagnosis and AC
aggressiveness. Among the major reasons for the lack of reliable diagnostic biomarkers are the extraordinary
heterogeneity of the cancer cells, complex and poorly understudied interactions of the AC cells with adjacent
tissue and immune system, gene variation across patient cohorts, measurement variability, small sample sizes and
sub-optimal analytical methods. We suggest that gene expression profiling of the primary tumours and adjacent
tissues (PT-AT) handled with a rational statistical and bioinformatics strategy of biomarker prediction and validation
could provide significant progress in the identification of clinical biomarkers of AC. To minimise sample-to-sample
variability, repeated multivariate measurements in the same object (organ or tissue, e.g. PT-AT in lung) across
patients should be designed, but prediction and validation on the genome scale with small sample size is a great
methodical challenge.
Results: To analyse PT-AT relationships efficiently in the statistical modelling, we propose an Extreme Class
Discrimination (ECD) feature selection method that identifies a sub-set of the most discriminative variables (e.g.
expressed genes). Our method consists of a paired Cross-normalization (CN) step followed by a modified sign
Wilcoxon test with multivariate adjustment carried out for each variable. Using an Affymetrix U133A microarray
paired dataset of 27 AC patients, we reviewed the global reprogramming of the transcriptome in human lung AC
tissue versus normal lung tissue, which is associated with about 2,300 genes discriminating the tissues with 100%
accuracy. Cluster analysis applied to these genes resulted in four distinct gene groups which we classified as
associated with (i) up-regulated genes in the mitotic cell cycle lung AC, (ii) silenced/suppressed gene specific for
normal lung tissue, (iii) cell communication and cell motility and (iv) the immune system features. The genes
related to mutagenesis, specific lung cancers, early stage of AC development, tumour aggressiveness and
metabolic pathway alterations and adaptations of cancer cells are strongly enriched in the AC PT-AT discriminative
gene set. Two AC diagnostic biomarkers SPP1 and CENPA were successfully validated on RT-RCR tissue array. ECD
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any medium, provided the original work is properly cited.method was systematically compared to several alternative methods and proved to be of better performance and
as well as it was validated by comparison of the predicted gene set with literature meta-signature.
Conclusions: We developed a method that identifies and selects highly discriminative variables from high
dimensional data spaces of potential biomarkers based on a statistical analysis of paired samples when the number
of samples is small. This method provides superior selection in comparison to conventional methods and can be
widely used in different applications. Our method revealed at least 23 hundreds patho-biologically essential genes
associated with the global transcriptional reprogramming of human lung epithelium cells and lung AC
aggressiveness. This gene set includes many previously published AC biomarkers reflecting inherent disease
complexity and specifies the mechanisms of carcinogenesis in the lung AC. SPP1, CENPA and many other PT-AT
discriminative genes could be considered as the prospective diagnostic and prognostic biomarkers of lung AC.
Background
Lung cancer is the leading cause of cancer deaths in the
world [1-5]. It is very heterogeneous and high-risk mor-
tality genetic disease. Non-Small Cell Lung Cancer
(NSCLC) is the major type of human lung cancer. The
most common histologic sub-type of NSCLC is lung ade-
nocarcinoma (AC). AC is a long-term disease that takes
10 to 30 years to manifest. AC is characterized by dra-
matic gene expression changes in tumour cells and has a
high chance of early metastasizing, due to the inherent
molecular abnormalities of lung cancer cells and the pre-
sence of an extremely dense blood and lymph vessel net-
work. Haematogenesis and lymph dissemination can
spread the cancer to other lobes of the lung, liver and
brain even on the early stages of the disease. Many mod-
els of AC development and progression have been dis-
cussed in the literature [1,2,6-8]. However, the genetic
mechanisms of the early stages of primary lung AC pro-
gression and metastasis are poorly understood.
Diagnosis and prognosis at early stages of the AC are a
key factor for treatment outcome
Patients with lung AC have better survival rate when the
localized tumour is removed at an early stage [4]. How-
ever, current clinical instrumental methods for diagnos-
tics of lung cancers (including AC), such as CT-scan, X-
ray screening are still not sufficient for reliable early
diagnostics of AC and prognosis of early metastasis. In
contrast to breast cancer clinical biomarkers, current
status of the early diagnostic, prognostic and predictive
gene expression signatures in non-small-cell lung cancer
have failed to establish the usefulness of the gene mar-
kers over or above known clinical risk factors [1,2]. In
particular, there is currently no clinically applicable gene
test for the diagnosis and prognosis at early stage of AC
[1,2,6].
The currently available AC gene signatures demon-
strate substantial differences in both the number of pre-
dicted genes and the specific genes they include, mostly
due to differences in the study design, assay platforms,
tumour histology and patient selection protocols. Only
few of the studies in the field produced detailed clinical
and research protocols that were statistically and biolo-
gically validated [6-9]. Additionally, small sample size,
noise and unresolved problems of massive data integra-
tion reduce the power of the test for discriminatory bio-
logical variables and clinically important predictors.
Divergence and poor overlap of the AC and other lung
tumours gene signatures suggests that our knowledge
about nature and space dimensionality of tumour-asso-
ciated genes (and potential biomarkers) is essentially
incomplete [8-12]. All these questions are important in
assessing the biological complexity of the tumours and
the optimization of research and clinical study strategies
[13]. To address them, the biological, clinical and popu-
lation variations, the limited sample size and the sensi-
tivity/specificity of the diagnostic/prognostic biomarker
selection method (feature selection) should be taken
into account.
Perspective molecular markers for diagnostics,
classification and staging of AC development and AC
patient’s stratification
Using microarray technology, several putative gene mar-
kers of lung AC have been intensely studied and evalu-
ated in clinical trials, for example EGFR [13] and
osteopontin (SPP1) [14]. Other prospective gene mar-
kers, such as ERBB3 [15], MALAT1 [16], S100A2
[17-19], S100A6 [20], TCF21 [21-23], ABCC3 [21] and
ELN3 [24] have been found and validated in indepen-
dent studies. For example, S100A2 (S100 calcium bind-
ing protein A) is suspected to have a function of
tumour suppressor. Therefore, it can be considered to
be a promising cancer prognostic marker [19]. Cur-
rently, currently there is no clinically applied gene test
for early diagnostics, prognosis and prediction of
response to lung AC therapies [3].
Paired independent and dependent design of clinical
genomics study
The experimental design and the properties (or models)
of the feature selection method for biomarkers
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Page 2 of 24prediction are two important decision steps preceding
the actual data analysis. Their choice might significantly
affect the sensitivity and specificity of the findings, given
a high dimensionality of the data and the numerous
error sources that affect them.
In contrast to studies based on unpaired data (inde-
pendent patient samples for case and control), paired
data experiments have not been extensively applied in
feature selection of transcriptome studies aiming to bio-
marker identification [9,25,26]. However, due to the het-
erogeneous nature of the cancer genetics it is natural to
consider the use of paired measurements (disease vs.
control tissue design) originating from the same test
object (a patient)[27,28]. The paired microarray data
analysis compares the repeated measurements within
subjects, rather than across s u b j e c t s ,a n d ,i no u rc a s e
could increase the power of the test: multivariate paired
sample design study of dependent samples obtained
from the same object (a patient) could reduce the cross-
population and technical variability, increase the specifi-
city in the identification of highly discriminative fea-
tures, increase the sensitivity of diagnostic and
prognostic biomarker selection and facilitate disease
personalization.
Haney et al. [27] showed essential improvement in the
identification of differentially expressed genes when
paired designs were used compared to independent
sample designs. No tests were performed to determine
the benefit of using different statistical procedures for
paired dependent designed microarray datasets. The per-
formance of various statistical or computational simula-
tion methods on pair-designed microarray datasets was
not sufficiently evaluated [27,28]. Interestingly, a huge
improvement has been observed in DNA copy number
variation (CNV) analysis when paired dependent design
was used; more reliable and larger fraction of copy num-
ber variations at the genome scale were detected com-
pared to non-paired controls [29-31]. Ideally, CNV
analysis of normal tissue samples processed simulta-
neously with the tumour specimens would eliminate
technical noise variability and batch effects [29]. Addi-
tional advantages of paired comparisons include the
suppression of copy number aberrations present in both
normal and tumour tissues [29]. Till recently, paired tis-
sue samples were rarely available and acquisition of
paired normal tissue did not typically fall within the
purview of therapeutic surgical intervention. Conse-
quently, normal CNV profiles are often derived from a
variety of normal specimens accumulated in a laboratory
or rely on data obtained from other laboratories
employing the same CNV platform and/or comparison
with a publicly accessible database. Heinrichs et al [30]
used myeloid malignant samples to demonstrate the
superiority of matched tumour and normal DNA
samples (paired studies) over multiple unpaired samples
with respect to reducing false discovery rates in high-
resolution single nucleotide polymorphism array analy-
sis. The advantages of paired design in CNV analysis
was also suggested by Wu et al [31]. In view of the
above, we propose a new statistical procedure to identify
highly-discriminative genes from microarray paired
dependent studies.
We suggest that analysis of gene expression data of
the primary PT-AT handled with a rational computa-
tional strategy of biomarker prediction essentially facili-
tates personalized identification of a comprehensive set
of specific AC signatures, disease-specific pathways and
clinical biomarkers.
Within this framework, the primary aim of this work
was to design a feature selection (e.g. class discrimina-
tive genes) method that is capable not only of identify-
ing conventional ‘differentially expressed genes’ [32-36],
but also of predicting new genes that are biologically
meaningful and more clinically useful. The secondary
aim was to use new methodology to identify important
diagnostic and prognostic lung AC biomarkers. We
achieved these aims by (i) cross-normalization of the
initial dataset, (ii) selection of highly-discriminative gene
sets using non-parametric tests, (iii) automatic clustering
of selected genes into biologically meaningful groups,
(iv) prediction of the prospective lung AC diagnostic
biomarkers and (v) validation of the predictive metho-
dology based on a comprehensive list of previously char-
acterized gene markers of lung AC and tissue array
validation of the selected discriminative genes. Further
we discuss how our and other feature selection methods
could be improved and used to predict novel gene mar-
kers and critical disease-associated molecular pathways.
Results
Cross normalization of expressed genes in paired
dependent samples improves the discrimination ability of
previously characterized gene markers
We introduce a function to characterise the completely
discriminative variables (e.g. gene expression signals in
microarray data set) which according to some additional
statistical and biological criteria might be considered as
the potential clinical biomarkers (see Introduction and
Discussion).
Let X and Y represent the normal (adjacent) and
malignant paired dependent tissue samples (X,Y),
respectively. The paired signals for microarray identifica-
tor j, II ij
X
ij
Y , () (i =1 …,N ;j =1 ,…,M ;Xi sn o r m a l
class; Y is tumor class), are derived from N patients.
The sub-set of N paired dependent signals from quanti-
tatively distinct sample sets is called a completely discri-
minative signal (CDS) if:
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ij
Y
i
N
:=< {} =
= ∑1
1
where 1{.} is an indicator function with value 1 if the
expression in brackets holds and 0 otherwise. When
sN < , the signal is called incomplete discriminative sig-
nal (IDS).
Even if all paired samples are CDS in a given patient
cohort, the increase of the number of patients (or sam-
ple size) should lead to failure of “completeness” of a
given discriminative feature.
In order to select the prospective gene markers of AC
and evaluate potential biomarker space of AC, we used
54 U133A Affymetrix microarray designed in pairs: lung
AC versus surrounding lung tissue, which have been
obtained from 27 lung AC patients [37]. The MAS5
normalized expression data and the patients’ clinical
information were obtained from NCBI’s GEO database
(http://www.ncbi.nlm.nih.gov/geo/) using the GEO
accession number GSE7670 and [37]. Figure 1 shows
t h ew o r kf l o wo fo u rd i s c r i m i native feature selection
method and more details are described in Methods.
We used the sign symmetry test to estimate the p-
value, p, of having random classification on two groups
(Methods). In particular, in the extreme case of CDS (i.
e. no misclassification) for our 54 samples (27 paired
samples) after Bonferroni adjustment we get the p-value
estimate p =× 16 6 .1 0
-4 (i.e. no misclassification). At
one (of 27 pairs) misclassification errors we get
p =× 46 5 .1 0
-3 and at two (of 27 pairs) misclassification
errors we get p =× 63 0 .1 0
-2 . At the 93% confidence
level, the significance of the above p-values indicates
that CDS is not by chance.
In this work mostly CDS expression signals are con-
sidered as the prospective gene markers. However, a
relatively weak relaxation of the extreme criteria (a few
misclassifications) is also considered, but at specified
statistical conditions (Methods and Discussion). In our
feature selection method we used cross-normalization
(CN) method followed by our modified Wilcoxon sign
rank test (MWT) (Figure 1, Methods).
To demonstrate a performance of CN and MWT with
respect to its discrimination ability of the gene expres-
sion paired samples, we started with several well-defined
gene markers of lung AC: EGFR [38-44], osteopontin
(SPP1) [14], XAGE-1, [2,45-47], S100A2 [17-19], and
CBLC [48]. The probe sets 201983_s_at (as well as
201984_s_at, 211607_x_at), 209875_s_at, 220057_at,
204268_at and 220638_s_at correspond to these genes,
respectively. Figure 2 shows that the CN provides signif-
icant improvement of the separation of the paired
microarray signals for all discussed gene markers of
lung AC.
We also re-analysed the five-gene lung AC diagnostic
signature, which was identified from protein network
analysis combined with the microarray gene expression
data analysis [3]. This signature includes MYST3,
CDK7, BRCA1, EHMT2 and E2F1 genes, represented on
the U133A chip by the probe sets 202423_at,
211297_s_at, 204531_s_at, 202326_at, 2028_s_at, respec-
tively. We compared the results of the classification of
27 paired samples based on the initial (MAS5.0-normal-
ized) U133A data (GSE7670) [37] and based on addi-
tional data treatment,- mutual cross-normalization
(Methods).
Figure 3 shows the fractions of the paired samples that
correctly discriminate the AC samples vs. the surround-
ing tissue samples for the initial (MAS5.0-normalized)
U133A probe sets and for that data after application of
the mutual cross-normalization procedure. In some
cases, the distinction between adjacent lung tissue and
cancer tissue was quite strong (e.g. MYST3 (202423_at),
but in general, the paired CN yielded smaller numbers
of discrimination errors or even complete separation of
the normal and cancer samples (e.g. 202326_at,
202423_at). Figure 3 shows four examples, which
demonstrate the influence of CN in enhancing the
reparability of AC vs AT in 27 sample pairs rank-
ordered by the value of expression signal in AC samples.
Figure 1 Work flow of the discriminative feature selection method
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Figure 2 The classification accuracy before and after cross-normalization of the original MAS5-normalized data. Panel A depicts the
improvement of the classification accuracy of selected, well-established lung AC gene markers. Panel B depicts the improvement of the
classification accuracy of 5 gene signatures of lung AC [3].
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Page 5 of 24Thus, CN provides a systematic improvement of the
separation ability of the paired microarray signals for
well characterized biomarkers of AC and for gene mar-
kers of the AC diagnostic signature [3] having a high
discrimination ability of lung AC versus adjacent lung
tissue.
ECD identifies 2,829-signals signature and reveals the
global genome reprogramming in AC cells
Our task here is to identify extremely discriminative
gene expression signals (Methods, Figure 1) using 27
pairs of lung ACs and surround normal lung tissues.
Using 22,283 U133A Affymetrix probe sets GSE7670
and applying consequently CN and MWT, we extracted
a set of 2,967 Affymetrix U133A providing complete
sample separation. The bootstrap version of ranked
Welch test [35] p-value at a = 5% (Figure 1, Methods)
was then applied to select 2,829 statistically significant
probe sets (expression signals) (95% of the 2,967 identi-
fied initially), representing by 2,282 different GeneCards
gene IDs (sheets S1a-S1c Additional file 1). This set we
defined here as the PT-AT extremely discriminative
classifier. These results demonstrate high sensitivity of
our method and suggest a global reprogramming of
lung AC cell genome in comparison with the genomes
of the surrounding lung tissue cells.
ECD signature is strongly overlapped with previously
reported AC –associated gene sets and includes key
functional gene subsets
Further we assessed overlap of the PT-AT ECD classifier
with Significance Analysis of Microarrays (SAM) classi-
fier derived in this work using data [49], which consists
of expression profiles represented by 12,600 probe sets
detected in the normal and lung tumour tissues.
According to the filtering clinical and histologic data,
we pre-selected 79 U95A Affymetrix microarrays profil-
ing 17 normal lung tissue samples and 62 AC tissue
samples [49]. We used SAM method [50] at 5% local
false-discovery rate SAM (FDR) score, which selects
1717-probesets AC signature. 1141 of the 1717 probe
sets represent 1006 up-regulated AC genes and 563
probe sets represent 495 down-regulated AC genes
(sheet S1.d in Additional file 1).
These data integration results demonstrate a good
agreement between SAM U95A signature and ECD
U133A signature: 604 Refseq genes are common (Figure
4). 262 of the 604 genes are up-regulated and other 342
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Figure 3 The influence of the Cross normalization in enhancing the separability of paired samples is illustrated for selected genes
from well-established Lung AC gene markers (panel A) and a 5-gene lung AC signature[3]. The patients are rank ordered, based on the
cross-normalized expression intensities of the tumor samples.
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Page 6 of 24of the 604 genes are down-regulated in AC. Fold change
enrichment of the common gene terms in up-regulated
genes and down-regulated genes versus random co-
occurrence events is 3.32 and 7.27, respectively. The
hypergeometric test with extremely significant p-values
(6.55e-104 and 1.71e-173 for up- and down- regulated
AC genes, respectively) suggests the high agreement rate
among the gene signatures. A high degree of overlap-
ping is found in spite of differences in (i) microarray
types (U133A [37] and U95A [49]), (ii) experimental
designs (paired and independent sets), (iii) feature selec-
tion methods (ECD and SAM) and (iv) difference of the
ethnic groups studied in [37] (Chinese) and in [49]
(American).
The GO enrichment analysis, performed with the
PANTHER GO tools, shows the pronounced differ-
ences between terms of up- and down-regulated GO
categories of ‘Biological Process’, ‘Molecular Function’
and ‘Pathway’ annotation categories (sheet S1d in
Additional file 1). The up-regulated AC gene set over-
represented by the genes involved in primary meta-
bolic, carbohydrate metabolic process, nucleobase,
nucleoside, nucleotide and nucleic acid metabolic pro-
cess nucleoside, purine metabolism, de novo purine
biosynthesis, cell cycle and mytosis, glycolysis, nucleic
acid binding, succinate to proprionate conversion and
methylmalonyl pathway. For the case of AC down-
regulated categories, significant categories include
immunity and defence, interleukin signalling pathway,
mesoderm development, cell structure and motility,
signal transduction, cell surface receptor mediated sig-
nal transduction, cell communication, intracellular sig-
nalling cascade, cell structure cell adhesion, cell
motility (Figure 4, sheet S1d in Additional file 1).
Importantly, one of the most strongly suppressed gene
groups in lung AC is an immunity gene group. We
found that these 87 ECD AC down-regulated genes
could be consisting of a novel immune system signa-
ture of AC (S1e in Additional file ). We found also
that 59 AC up-regulated gene subset which could be
consisting of a novel cell cycle signature of AC (S1e in
Additional file ). These novel signatures might be used
for a future development of the diagnosis, monitoring
and prognosis of the AC patients.
Thus, our bioinformatics analysis strongly supports bio-
logical significance of at least 604 genes suggesting the
clinical importance of the ECD-derived gene signature.
Classifiers derived by PAM and EDGE methods
The application of the prediction analysis for microarrays
(PAM) method [51] to the data under study produced a
77 probe set classifier, which had the higher specificity but
the lower power, in comparison to other methods (see
next section for further details). However, to facilitate
comparison with other methods (see below), the genes
were sorted with the differences between PAM up- and
down- ‘Tumour scores’, and the desired numbers of genes
were then selected for further studies. The optimal discov-
ery procedure (ODP) method implemented in the EDGE
program was applied to our dataset to identify the best
AC-ST classifier of 996 unique, differentially expressed
genes with high statistical significance (q-value<2.75e-05)
(Additional file 1, Table S2.A in Additional file 2). These
differential probe sets constitute about 4.4 % of the total
probe sets represented on the arrays. To allow comparison
with other methods, the probe sets were ranked using the
‘FDR values’ and the desired numbers of probe sets were
then selected for further studies.
p-value=1.1e-173  p-value=7.27e-104 
Figure 4 Venn diagram analysis of the reproducibility of classifiers derived using two different Affymetrix platforms. The high degree
of overlap is interesting, given the different microarray experimental designs (the U133A classifier was derived using paired design, while the
U95A classifier was derived using un-paired design). The p-value, which reflects the significance of the overlap between the 2 sets, was
estimated using Fisher’s exact test [54].
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feature selection methods
To further assess the feature selection performance of
ECD, we decided to overlap the top 2,829 ECD-selected
probe sets with the top 2,829 probe sets derived by
EDGE, PAM, Wilcoxon and t-tests. The Venn diagram
in Figure 5 depicts a high fraction of overlapping (about
70% of the each group count) among the groups. How-
ever, when a complete ECD signature was compared
using the best differentially expressed gene signatures of
alternative methods, the ECD provides significantly lar-
ger number of the genes separating AC and AT samples
(Figure 6). On the same time, each alternative method
produces a proportion of the genes producing non-zero
misclassification error rate (Additional file 1, Table S2.A
in Additional file 2).
When the CN data were used for analysis of classifica-
tion accuracy of the methods, the ECD set provides the
highest, closely followed by the standard Wilcoxon sign
ranked test, EDGE and the t-test. While none of 2,829
probe sets from the ECD had 2 or more misclassified
sample pairs, the same-size top discriminative sets from
the standard Wilcoxon sign ranked, EDGE, the t-test
and PAM had 90 (3%), 111 (4%), 105(4%) and 335 (12%)
probe sets with 2 or more misclassified sample pairs,
respectively (Table 1). Thus, CN method improves
Figure 5 Venn diagrams illustrating the degree of overlap between the statistically significant probe sets identified by the Modified
Wilcoxon test, with the corresponding probe sets identified by other methods (WT, t-test, PAM and EDGE). Panel A: Venn diagram
illustrating the overlap between the MWT classifier and the top 2,829 differentially expressed probe sets, rank ordered using FDR values and
identified using canonical approaches (t-test and WT with FDR correction). Panel B: Venn diagram depicting the overlap between the MWT
classifier and the top ranked probe sets identified using computationally intensive feature selection methods.
Figure 6 Venn diagrams illustrating the overlap of the
classifiers derived using EDGE, PAM, WT and ECD. Panel A:
Venn diagram depicting the overlap of the U133A probe sets
identified as highly discriminative features. Panel B: Venn diagram
depicting the overlap between the RefSeq gene symbols
corresponding to the above described U133A probe sets. The
numbers in parentheses are the numbers of known gene symbols
present in a given subset.
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Page 8 of 24selection accuracy for the each method used in a feature
selection. The improvement effect of CN method was
particularly striking for MWT, where the classification
errors, in terms of the number of probe sets with two or
more misclassified sample pairs, decreased from 77.4%
in the initial MAS5 normalized dataset to 0% in the CN
dataset.
As we expected, CN also produces a substantial
improvement in the classification accuracy of the top
2,829 probe sets identified using other methods. While
the misclassifications, in terms of the percentage of
probe sets with two or more sample pairs, in the MAS5
normalized data were 76.2, 77.3, 76.2 and 76.3 for the
top 2,829 probe sets identified using by EDGE, PAM,
the standard Wilcoxon test and the t-test, respectively,
the false classifications for the corresponding probe sets
using the CN data were 4%, 12%, 3% and 4%, respec-
tively (Table S2.A in Additional file 2).
The functional clusters of the lung PT-AT extremely
discriminative genes
When hierarchical clustering analysis (without sample
pairing) was applied to 54 samples represented by the
top-selected 2,829 probe sets, each of the feature selec-
tion method could clearly discriminate tumour samples
from all normal samples (Figures S1-S4 in Additional
file 3). However, CN produces fewer and more distinct
gene clusters with enhanced difference between lung
AC and normal samples (Figure 7; Figures S1-S4 in
Additional file 3). Thus CN can be applied after the
standard feature selection methods in order to increase
Table 1 Distribution of the number of false classifications of the 27 paired samples.
False classifications MWT EDGE PAM Students t-test Wilcoxon test
Up-regulated in tumours 0 1628 1109 938 1087 1054
1 0 202 211 184 187
2 0 27 73 20 14
30 1 2 5 0 0
40 0 6 0 0
90 0 1 0 0
Down- regulated in tumours 8 0 0 1 0 0
70 0 1 0 0
60 0 2 0 0
50 0 1 2 0 0
40 3 2 9 2 2
3 0 16 67 15 10
2 0 64 118 68 64
1 0 317 314 343 372
0 1201 1090 1031 1110 1126
# of the probe sets with 2 or more misclassified pairs 0 111 335 105 90
total # of probe sets 2829 2829 2829 2829 2829
percent of probe sets with 2 or more misclassified pairs 0 0.04 0.12 0.04 0.03
Comparison of the classification accuracy of highly discriminative 2829 probe sets (selected using MWT on cross-normalized signal intensity values with a
stringent 100% accuracy criteria and a bootstrap p-value cut-off<0.05) with top-level 2829 probe sets identified by standard Wilcoxon sign ranked test (WT),
EDGE, PAM, and student&#8217s t-test. While the ECD classifier was derived using cross-normalized dataset as input, the classifiers derived using PAM, EDGE, WT
and t-test used the original MAS5-normalized data as input. However the classification accuracy in terms of the number of probe sets with 2 or more anomalous
fold changes was estimated using the cross-normalized dataset.
Figure 7 Heatmap depicting four gene clusters which perfectly
separate the AC and the surround lung tissue samples. The
similarity of the profiles was estimated using two-way hierarchical
cluster analysis of the cross-normalized expression signal intensity
values. The panel on the left of the heatmap shows the distribution
of fold-changes of individual probe sets, ranked based on Euclidian
distance metric. The distribution of the fold-change values specifies
AC up- and down- regulated gene clusters.
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Page 9 of 24the method performance. Furthermore, the gene clusters
derived from the cross-normalized expression data are
also comparatively better enriched in the top level gene
ontology (GO) terms.
Interestingly, GO enrichment analysis of the common
biological terms reveals systematically stronger p-value
of the enrichment of ECD classifier vs. alternatives. For
instance, Table S2.B of Additional File 2 shows overre-
presentation of cell cycle related genes containing in
ECD gene signature vs. EDGE gene signature.
The hierarchical clustering analysis of the ECD signa-
ture grouped the genes into four distinct clusters: clus-
ter 1 (397 probe sets ( p.s.); 342 Refseq genes) and
cluster 3 (803 p.s.; 673 Refseq genes) contain down-
regulated genes, while cluster 2 (1301 p.s.; 1101 Refseq
genes) and cluster 4 ( 328 p.s. ; 264 Refseq genes ) con-
tain the genes that are up-regulated in the lung AC vs
AT (Figure 7).
Inflammatory response, regulation of cytoskeleton
organization, wound healing, negative regulation of cell
proliferation and regulation of immune response are
some of the categories highly enriched in cluster 1,
while enzyme linked receptor protein signalling pathway
and metal ion homeostasis are some of the highly
enriched categories in cluster 3 (Table 2). Among the
highly enriched and interesting categories in clusters 2
and 4 are M-phase of mitotic cell cycle, negative regula-
tion of intracellular transport, response to DNA damage
Table 2 Selected GO terms and selected genes illustrating the functional categories enriched in the clusters of
discriminative genes derived using ECD (Figure 7). Several representative gene symbols are indicated in parentheses.
Cluster 1
￿Inflammatory response [AGER, ALOX5, MYD88, SEPP1, SERPING1]
￿Regulation of cytoskeleton organization [ABLIM1, DES, DST, NEDD9, PALLD, PRF1]
￿Positive regulation of response to stimulus [C1QA, C1QB, C7, CADM1, CX3CL1, FABP4, FCER1G, MYD88, SERPING1, SLIT2]
￿Wound healing [CD36, GNAQ, HBEGF, MYH10, SERPING1, THBD, VWF]
￿Response to mechanical stimulus [BTG2,TIM2, CAV1,CCL2, MGP,TXNIP,TGFBR2, FOS]
￿Negative regulation of cell proliferation [SFTPD, VSIG4]
￿Regulation of locomotion [EGFL7,CLIC4,AGER, DLC1,ENPP2,EDN1, IL6, IL6ST, VCL]
￿Complement activation [C1QA, C1QB, C7, SERPING1]
￿Positive regulation of immune response [C1QA, C1QB, C7, CADM1, FCER1G, MYD88, SERPING1]
￿Hormonal immune response[C1QA, C1QB, C7, CCL2, IL6, SERPING1] 1, FCER1G, MYD88, SERPING1]
Cluster 2
￿M phase of mitotic cell cycle [AURKA, BIRC5, BUB1,CCNB1, CENPE]
￿Negative regulation of intracellular transport [BARD1, GSK3B, NCBP2, NF1, TACC3]
￿Microtubule-based process [CEP250, DST]
￿Response to DNA damage stimulus [CSNK1D, DDB1, NONO,POLD1, TOP2A]
￿Spindle organization [AURKA, BUB1B, CKS2, TTK, TUBG1, ZWINT]
￿Cellular protein localization [AP1B1, ARF5, ICMT, NUP62, TIMM13, TOM1L1]
￿DNA repair [APEX1, CSNK1D, DDB1, HMGB2,PARP1,POLB, POLD1,TOP2A]
￿Glycosylation[ALG6,FUT2,GALNT10,MGAT4B, OGT, STT3A, UGCGL1]
Cluster 3
￿Enzyme linked receptor protein signaling pathway [ADRB2, ARRB2,SPTBN1, TEK, TGFBR3, ZFP106]
￿Metal ion homeostasis [AGTR1, C5AR1, RGN, S1PR4, TRPC6]
￿Protein amino acid phosphorylation [AATK, ADRB2, TIE1, TTN, ULK2]
￿Transmembrane receptor protein tyrosine kinase signaling pathway [ADRB2, CRYAB, SORBS1, TEK, ZFP106]
￿Negative regulation of cell proliferation [ADAMTS8, AIF1, TENC1, TGFB1I1, TOB2]
Cluster 4
￿Collagen fibril organization [COL3A1, COL5A2]
￿Glycolysis[ALDOA, ENO1, GAPDH, PKM2, TPI1]
￿Carbohydrate catabolic process [ALDOA, ENO1, FUCA1, GAPDH, TPI1]
￿Extracellular structure organization [AGRN, COL11A1, COL3A1, COL5A2, ERBB2]
￿Collagen metabolic process [COL3A1, MMP1, MMP11, MMP7]
￿Negative regulation of cell adhesion [CDKN2A, HNRNPAB, TGFBI]
￿Generation of precursor metabolites and energy [ALDOA, ENO1, GAPDH, UQCRH, UQCRQ]
￿Negative regulation of protein ubiquitination [PSMA1,PSMA2, PSMB2, PSMB3, PSMB4, PSMB5]
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tion, glycolysis, focal adhesion and extracellular struc-
ture organization (Table 2). The biological categories
and pathways identified here strongly suggest that the
responses to external stimuli and the micro-environ-
mental organization are highly reactive and intercon-
nected to the progression steps of the lung AC via the
mitotic cell cycle.
The ECD-based PT-AT signatures are strongly associated
with AC, other lung cancers and lung diseases
Next we studied the disease association of the four clus-
ters of the lung AC discriminative signatures using Gen-
eGO Diseases module, which links over 500 human
diseases with genes. The GeneGO Diseases module
prioritized 10 most highly enriched disease categories
ranked according to p-value enrichment. The p-value
enrichment values calculated with GeneGO takes into
account the gene content variation between complex
diseases, such as cancers and some Mendelian diseases
in addition to the biased coverage of different diseases
in literature. The top 10 enriched diseases for the 4
clusters of our signatures were strongly associated with
lung cancers and bronchial/respiratory track diseases
(Figure 8). Thus, our molecular classifier can be split
into four functionally distinct groups, which are highly
specific to AC and other lung tumours and lung
diseases.
The gene clusters of extremely discriminative gene
signatures are associated with metabolic pathway
alterations and environment adaptations
The metabolic pathway alterations and environment
adaptations of cancer cells is an important area of anti-
cancer drug discovery research. The metabolic pathways
may create a phenotype that is essential for tumor cell
growth and survival, altering the flux along the key
metabolic pathways, such as glycolysis and glutaminoly-
sis [52,53]. In context of the enrichment analysis of
metabolic networks in Lung AC, we applied GeneGo
Metabolic Networks enrichment analysis. Figure 9
shows interesting association of our clusters of discrimi-
native genes with metabolic networks. For example,
clusters 2 and 3 are enriched in glycerol-3-phosphate
metabolic pathways, malto-hexaose/-pentose pathways
& N-acyl-sphinngosine phosphate pathway, while cluster
4 is significantly enriched in genes of carbohydrate
metabolism, glycolysis, glucogenesis and glucose trans-
port pathway. The alterations in these metabolic path-
ways could lead to changes in the concentration of
cognate metabolites. These metabolites could be easily
detected in body fluids by non-invasive assays and
hence have a great potential for the development of
non-invasive diagnostic kits of lung AC.
ECD signatures highly enriched with many previously
characterized gene markers
To evaluate the signatures derived from different feature
selection methods (Methods) on the 27 PT-AT paired
lung AC sample U133A dataset (Dataset section in
Figure 8 GeneGo disease association analysis. Sorting of the
GO term enrichment is done by p-values. The p-value is
estimated by GeneGo MetaCore ‘Statistically significant Diseases’
method. Yellow: cluster 1, blue: cluster 2, read: cluster 3, and green:
cluster 4. Selected genes of the GO clusters are described in Table
2. Cluster 1 (top) includes genes of Inflammatory response,
Regulation of cytoskeleton organization, Positive regulation of
response to stimulus, Wound healing, Response to mechanical
stimulus, Negative regulation of cell proliferation, Regulation of
locomotion, Complement activation, Positive regulation of immune
response, Hormonal immune response. These genes are suppressed
in AC vs AT. Cluster 2 includes the genes of M phase of mitotic cell
cycle, Negative regulation of intracellular transport, Microtubule-
based process, Response to DNA damage stimulus, Spindle
organization, Cellular protein localization DNA repair, Glycosylation.
These genes are overexpressed in AC vs AT. Cluster 3 includes the
genes of Enzyme linked receptor protein signalling pathway, Metal
ion homeostasis, Protein amino acid phosphorylation,
Transmembrane receptor protein tyrosine kinase signalling pathway,
Negative regulation of cell proliferation. These genes are suppressed
in AC vs AT. Cluster 4 includes the genes of Collagen fibril
organization, Collagen metabolic process, Glycolysis, Carbohydrate
catabolic process, Extracellular structure organization, Negative
regulation of cell adhesion, Generation of precursor metabolites and
energy, Negative regulation of protein ubiquitination. Cluster 4
includes the genes up-regulated in AC vs AT (Figure 7).
Figure 9 GeneGo metabolic networks analysis. Sorting of the
GO term enrichment is done by p-values. The p-value is estimated
by GeneGo MetaCore ‘Statistically Significant Networks’ method (see
Figure 7 for details).
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Page 11 of 24Methods), we catalogued approximately 100 references
cited as either lung AC prognostic- or diagnostic- bio-
markers and further manually selected 25 relevant publi-
cations and extracted set of 1,249 genes (Additional file
4). This gene set covers individual biomarkers as well as
multi-gene signatures and is called here AC Meta-signa-
ture. To get a more quantitative information about
expression profile of these genes in lung AC and to
develop comparative analysis of this gene subset vs.
other subsets (signatures), we integrated AC Meta-gene
signature information presented in the Additional file 4
into our gene expression ‘master table’(sheet S1 in the
Additional file 1). We used this set as a positive control
to evaluate the enrichment of gene signatures studied in
this work with the genes associated with lung PT-AT
discrimination and the genes which could be considered
as prospective clinical biomarkers.
The term enrichment of AC Meta-gene signature gene
markers in various signatures was analysed using a two-
sided Fisher exact test [54]. We tested enrichment of
Meta-gene signature gene markers with the best gene
signatures derived using EDGE, PAM and WT methods
and ECD method. We found that all studied classifiers
were significantly enriched with AC Meta-signature
genes. However, ECD provides more complete subset
found Meta-gene signature. The Fisher exact two-tail p-
values sorted by significance were 4.22E-57, 1.19E-46,
5.29E-16 and 2.02E-12 for the most highly discrimina-
tive gene signatures derived using ECD, EDGE, PAM
and WT, respectively.
AC meta-signature genes and ECD PT-AT signature
demonstrates high enrichment of mutagenesis sites and
cancer associated proteins
Table 3 presents the counts of common fraction and the
unique fractions of the genes found in the AC ECD and
AC Meta-signature, respectively. All these three sub-sets
are significantly enriched with the genes encoding the
proteins having UniProt DB mutagenesis sites (http://
www.uniprot.org/). These sites have been experimentally
altered by mutagenesis. UniProt DB describes the effect
of the experimental mutation of one or more amino
acid(s) on the biological properties of the protein. It
describes only those experiments in which a limited
number of amino acid residues were altered: gross
alterations in protein structure, such as the deletion of
hundreds of amino acids are not described.
In all, 366 UniProt proteins having mutagenesis site(s)
were found with our ECD signature. Among these pro-
teins, we found epidermal growth factor receptor (EGFR
: 201983_s_at; 201984_s_at, 211607_x_at), v-erb-b2 ery-
throblastic leukemia viral oncogene homolog 2, neuro/
Table 3 Enriched UP_SEQ Features terms in common and unique sub-sets of PT-AT ECD-derived signature and Lung
AC Meta-signature
UP_SEQ_FEATURE Count % P-Value Fold enrichment Benjamini FDR
Common sub-set
nucleotide phosphate-binding region:ATP 59 13.3 1.60E-11 2.7 2.60E-08 2.70E-08
mutagenesis site 95 21.5 2.90E-11 2 2.40E-08 4.90E-08
binding site: ATP 36 8.1 4.20E-08 2.9 2.30E-05 7.00E-05
domain: kinesin-motor 9 2 5.20E-06 9.1 2.10E-03 8.70E-03
signal peptide 112 25.3 5.80E-06 1.5 1.90E-03 9.80E-03
domain: MCM 5 1.1 1.80E-05 27.1 4.80E-03 3.00E-02
sequence variant 317 71.7 2.30E-05 1.1 5.30E-03 3.80E-02
domain: protein kinase 27 6.1 3.50E-05 2.5 7.10E-03 5.90E-02
active site: proton acceptor 33 7.5 5.80E-05 2.2 1.00E-02 9.70E-02
Discriminative signature: 2829 probes; unique 1862
mutagenesis site 271 15.4 3.70E-11 1.5 1.70E-07 6.90E-08
cross-link: Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin) 38 2.2 2.00E-05 2.1 4.40E-02 3.70E-02
binding site:substrate 50 2.8 2.90E-05 1.9 4.30E-02 5.40E-02
Meta-signature: 1249 probes; unique 806
domain: protein kinase 66 8.3 4.00E-18 3.4 9.90E-15 7.00E-15
nucleotide phosphate-binding region: ATP 99 12.4 3.20E-17 2.5 4.00E-14 5.70E-14
binding site: ATP 69 8.7 1.20E-16 3.1 9.20E-14 2.00E-13
mutagenesis site 160 20.1 6.90E-16 1.9 4.20E-13 1.20E-12
active site: proton acceptor 71 8.9 2.60E-13 2.6 1.30E-10 4.60E-10
nucleotide phosphate-binding region: GTP 28 3.5 9.10E-05 2.3 3.70E-02 1.60E-01
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Page 12 of 24glioblastoma derived oncogene homolog (avian) (ERBB2:
216836_s_at), MAD1 mitotic arrest deficient-like 1
(yeast) (MAD1L1; 204857_at), solute carrier family 22
(organic cation transporter), member 18 (SLC22A18;
204981_at) and tumour protein p73-like (TP63;
209863_s_at). Mutations in these well-known genes are
associated with lung cancer, and specifically AC cells
[3]. Interestingly, according to our finding all these
genes are overexpressed in AC vs. AT (Additional file 1)
and could be consists of as the prospective small signa-
ture to estimate the risk of occurrence and progression
of lung AC.
Table 4 shows the statistics of the proteins having
mutagenesis site(s) in the common and the unique pro-
tein subsets found in AC Meta-signature and in AC
ECD. In total, the signatures include 518 proteins with
the mutagenesis sites. A fraction of the proteins belong-
ing to the common subset (21.5%) is slightly higher than
that observed in the unique subsets of the Meta-signature
(20.1%) and DC (15.4%). These results suggest that muta-
genesis site-containing proteins can be often found in the
both of our signatures. Thus, both the Meta-signature
and the AC ECD signature sets are highly enriched with
genes encoding the proteins having mutagenesis site(s).
98 such proteins are common for the both AC signatures
and could be considered as the most prospective set of
the gene markers directly related to molecular mechan-
isms of carcinogenesis and progression of AC.
To better assess the functional annotation of the gene
markers enriched in our ECD classifiers, we will focus
now on the statistical enrichment analysis of gene set
with gene ontology terms (GO) [55].
Not only genes of “proliferative/cell cycle signature” but
many genes encoding proteins that produce signal
peptides and metabolic modifications are involved in the
development of AC
Interestingly, the term “signal peptide” is associated with
the proteins which belong to a common fraction (112
gene symbols) (Table 3). Interestingly, this GO category
term is not significantly enriched in the unique subset
of our AC Meta-signature and in the unique subset of
our discriminative AC signature. Reported peptides
could control the essential metabolic processes and
tumour development involved in local interaction of
tumour with stroma, immune and endocrine system and
surrounding cells of AC.
According to David Bioinformatics software, a com-
mon fraction of our discriminative AC and AC Meta-
signatures is also strongly enriched with the genes
encoding proteins of cell cycle, mitosis, micro-tubular
based processes, DNA replication, spindle organization,
regulation of cell cycle process and other GO terms
which are typically represented in many “proliferative
signatures” reported for many cancers. However, unique
subsets are represented by more diverse sub-sets
enriched with the specific GO terms. For instance, AC
Meta-signature is strongly over-represented by GO
terms “protein amino acid phosphorylation”, “phosphate
metabolic process”, “intracellular signalling cascade”,
“regulation of apoptosis”, while the unique subset of dis-
criminative AC signature is more than 2-times enriched
with the GO term “vasculature development” and 4.8
times enriched with the GO term “protein amino acid
O-linked glycosylation”. The genes representing these
two terms were reported in the literature to be the key
players in the early stage of cancer progression, tumour
dormancy and risk of tumours metastasis.
Early diagnostic and prognostic biomarkers
EF improves significantly when the early diagnostic bio-
markers reported in the literature were exclusively com-
pared with the best discriminative genes derived using
ECD and the alternative signatures. For instance, Table
5 lists 28 early diagnostic lung AC marker genes, FE of
these genes measured using the Fisher’s exact two-tail
p-values and the EF were 1.59e-7 and 3.76 respectively
for the proposed ECD and 9.82e-7 and 6.47 respectively
for EDGE. Most of EDGE selected genes are included in
the ECD set (Table 5, Additional file 1). As result, ILF3,
RETN1, MCM6, MUC4, supported from 2 to 4 studies,
where identified by ECD method only. Interestingly, sev-
eral genes of Table 5 could be considered not only pro-
spective diagnostics biomarkers, have been reported as
the prognostic biomarkers (see Table 5 references).
Among such ‘dual’ biomarkers we can indicate AURKA,
TOP2, ILF3, MCM6 and RFTN1 which should be test
as prospective diagnostic and prognostic biomarkers.
Thus, among studied feature selection methods, ECD
provides the most comprehensive lists of the genes
Table 4 Statistics of ‘mutagenesis site’ term in the common and the unique protein subsets found in the AC meta-
signature and AC ECD signature
Subsets #Reported genes # protein IDs #Mutagenesis site # proteins ID/# Mutagenesis site
Common genes 455 499 98 0.20
AC meta-signature only 829 813 162 0.20
ECD signature only 1852 1664 258 0.16
Total 3136 2926 518 0.19
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prospective genes for biomarker discovery.
The size of the ECD-derived PT-AT discriminative
signature can be extended to derive a classifier that pro-
vides better coverage of the AC Meta-signature. Many
AC Meta-signature genes are well characterized as pro-
mising lung AC biomarkers (for example, BRCA1 and
EHMT2, see also Figures 2 - 3). However, these gene
markers are not present in ECD-derived signature. On
the other hand, such gene markers could be found by
WMT and the following bootstrap selection when few
misclassification errors are allowed. According to pre-
vious estimates by the Sign test (Methods), we allow the
feature selection method to select discriminative U133
probe sets with 0, 1 and 2 misclassification errors. In
the case of two misclassification errors, ~7% (=(1-25)/27
x 100%) error rate might be acceptable according the
multivariate adjusted Sing test. To reduce the risk of
false positive selection, we limited the smallest fold
change (ratios AC/AT or AT/AC) of mean expression
signals in the paired data to higher than 1.2 and the
bootstrap method p-values to less than 0.01. By applying
these criteria, the ensuing PT-AT signature with 5,031
probe sets was obtained (Additional file 1). This discri-
minative set is also strongly enriched with known lung
AC meta-signature gene markers (Fisher exact two-tail
p-value=9.40E-127and FE = 2.34).
Table 5 shows that our relaxation of ECD selection
criteria increase a fraction of confirmed early diagnostics
genes from 62.5% (9/24) to 83.3% (20/24).
Thus, our extended PT-AT discriminative gene set
(Additional set 1) and its subset of AC early diagnostic
Table 5 PT-AT discriminative set and its extended set are significantly enriched by gene markers reported as potential
biomarkers for a diagnostic of the early stages of lung AC. The extended set was obtained by relaxing the default PT-
AT ECD signature at misclassification error values to 3. More details in see Additional file 4.
Early AC diagnostic signature genes
from [7]
#
Supporting
references
#
PT-AT extreme discriminative sign.
(2829 genes)
Extended set (misclassification
errors to 3)
EDGE
ATP10B [7] YES YES NO
AURKA [5][7] YES YES YES
CLDN5 [7] YES YES YES
COL11A1 [10][7] YES YES YES
DNAI2 [7] NO YES NO
FABP6 [7] NO NO NO
HIGD1B [7] YES YES YES
ILF3 [5][17][2] YES YES NO
IQCG [7] NO NO NO
LRRC48 [7] NO NO NO
LRRC50 [7] NO NO NO
MCM6 [5][7] YES YES NO
MUC4 [13][7] NO YES NO
RARRES2 [7][3] YES YES YES
RFTN1 [22][7][4][3] YES YES NO
SCG5 [7] YES YES NO
SCGB1A1 [9][7] NO YES YES
SFTPA2 [7] YES YES NO
SFTPB [7] NO YES NO
SFTPC [7] YES YES YES
TFPI2 [7] YES YES YES
TM4SF4 [7] NO YES NO
TOP2A [5][7][6] YES YES YES
XAGE1A [14][7] YES YES YES
XAGE1B [24][21][14][7] no U133A probe sets no U133A probe sets no U133A probe
sets
XAGE1C [14][7] no U133A probe sets no U133A probe sets no U133A probe
sets
XAGE1D [14][7] no U133A probe sets no U133A probe sets no U133A probe
sets
XAGE1E [14][7] no U133A probe sets no U133A probe sets no U133A probe
sets
# - The references mentioned in this table correspond to the citations used in Additional file 4.
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to discover novel biomarkers and to investigate already
reported promising gene markers.
Validation of the diagnostic utility of the proposed lung
AC ECD discriminative signature using tissue array assay
In order to validate the diagnostic utility of our discri-
m i n a t i v es i g n a t u r ew es e l e c t e dt w og e n e sS P P 1a n d
CENPA, both of which showed 100% separation with
strong fold change of PT-AT pairs in the U133A expres-
sion dataset. SPP1 is a well-characterized gene which is
considered as a promising prognostic and diagnostic
biomarker of NSCLC [13,14]. CENPA is a genomic mar-
ker for centromere activity and human diseases, includ-
ing cancer [56], but it is not established as an important
gene for lung AC diagnostics and prognosis.
The results of QRT-PCR tissue arrays of genes (SPP1
& CENPA) are completely concordant with the microar-
ray analysis (Additional file 1, Figure 10); these genes
perfectly discriminate 24 lung tumour samples from 24
adjacent normal lung samples. Additionally, QRT-PCR
Ct values also show strong fold changes of 28.6 and
16.0 for SPP1 and CENPA, consistently with microarray
expression fold-changes (Table 6), strongly suggesting a
possibility to consider this gene pair as a prospective
biomarker of lung AC.
Discussion
Advantages of the proposed ECD method
We demonstrate that the application of cross-class nor-
malized to dependent paired data increases the distance
between the objects of two classes and decreases the
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Figure10 QRT-PCR validation of potential lung AC diagnostic biomarkers identified using MWT. The separability of the normal-Lung AC
pairs of the potential lung AC gene markers identified using MWT on lung tissue QRT-PCR array is illustrated, before (A & C) and after (B & D)
application of the cross-normalized expression procedure to SPP1 (A & B) and CENPA (C&D).
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Page 15 of 24number of misclassification errors. The method allows
us to (i) better separate the samples of the two classes
(statistical issue), (ii) reduce the number of misclassifica-
tion errors (pattern recognition and machine learning
issues) in comparison with initial data, (iii) provide a
highly sensitive and ultra-specific feature selection pro-
cedure of the discriminative features (filtering signal-
noise issue) and (iv) select the most biologically reliable
classifiers (discriminative genes, novel gene markers)
representing the classes of interest (tumour and adjacent
tissues). Our feature selection model uses consequently
CN, MWT, and the bootstrap method and sign-rank
tests (figure 1). It selects the statistically significant fea-
tures (e.g. probe sets) focusing on the complete or
almost error-less separation of the dependent paired
samples when a limited number of samples is available.
Quality control of ECD classifier
We compared the feature selection method based on
ECD with the standard methods from the literature,
using our aforementioned quality control approach, and
then finally assess the efficiency of alternative classifiers
and our method, using a comprehensive set of known
gene markers of lung cancer. The efficiency of ECD
classifier was successfully evaluated in several ways: (i)
by the similarity in content between gene lists selected
from the same data[37] (microarray U133A) using ECD
and alternative feature selection methods, (ii) by the
similarity in content between the gene list selected from
the data [37] (microarray U133A) using ECD and the
gene list selected from independent data [49] (microar-
ray U95A) using SAM (Methods), (iii) by the enrich-
ment of previously reported lung AC gene markers in
ECD vs. AC Meta-gene signature set (iv) by the enrich-
ment of ECD classifier with previously reported lung
AC gene markers associated with early stage of the can-
cer progression, mutagenesis and/or risk of disease pro-
gression, (v) by RT-QPCR validation of the several
predicted biomarkers.
The similarity in content between gene lists derived from
different data sets
AC signatures reported in the literature have often
revealed little agreement in the gene lists produced by
different methods. For example, Jeffery et al [57] found
that only 8-21% of the genes were common across 10
selected features selection methods. However, the high
level of agreement between ECD signature derived from
data [37] and SAM signature derived from independent
data [49] not only suggest a pronounced content simi-
larity between gene lists, but also demonstrate much
higher sensitivity of ECG vs SAM. Thus, our method
has been shown to be highly specific and sensitive.
Effectiveness of the classifiers derived using ECD vis-a-vis
standard methods
The effectiveness of the classifiers derived using ECD
and the classifiers derived using standard method was
represented by the test p-values in lung AC- AT sample
p a i r sa tb o t hi n d i v i d u a lg e n ea n dt h eg e n eg r o u pl e v e l s .
Our comparative analysis of the selected gene signatures
derived by different methods demonstrates the highest
specificity and sensitivity of ECD. When cross-normal-
ized data were used, the superiority of the ECD classifier
at the pair level is particularly clear. All the probe sets
of the ECD classifier perfectly discriminated normal
lung from lung AC in all sample pairs. The selected
standard methods, such as EDGE, Wilcoxon and Stu-
dent’s t-test discriminated reasonably well too. Further-
more, all the methods are comparable, in terms of their
ability to discriminate groups of normal and lung AC
samples. However, a comparison of the classification
accuracy of the various classifiers, obtained from the
MAS5.0 normalized data, revealed essential improve-
ments in the discriminative ability obtained upon the
CN of the dataset. Moreover, in comparison to alterna-
tive methods, ECD classifier reveals four well-separated
gene clusters. These clusters provide a clear biological
interpretation of the grouped gene sets.
Table 6 QRT-PCR validation of potential lung AC diagnostic biomarkers identified using PT-AT ECD.
RefSeq gene (probe sets/primers) WT MWT Sample pairs Fold change (AC/N)
Dis. error P-value Dis. error P-value
SPP1 (209875_s_at) 1 6.28E-06 0 1.25E-05 28 16.90
CENPA (204962_s_at) 4 9.00E-05 0 1.25E-05 28 1.41
SPP1 (primer) 1 3.03E-05 0 4.07E-05 24 28.91
CENPA (primer) 1 2.35E-05 0 4.07E-05 24 15.25
Discrimination error (Dis. Error) is the number of misclassified pairs. Fold changes for microarray was estimated as the ratio of the mean expression values of AC
tissue versus adjacent normal tissue in the same tumour sample. Fold change for QRT-PCR was estimated as a ratio of the mean CT values (which were
normalized using Actin-B CT values as control) of lung cancer tissues versus adjacent normal tissues in the same tumour sample. For more details of expression
and QRT-PCR data normalization procedures, please refer to the materials and methods section.
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previously reported prospective biomarkers for early
tumour diagnostics, progression and patient survival
The GO analysis suggested the enrichment of our set of
predictors with oncogenes and tumour suppressor gene
markers. The identification of many well-defined cancer
gene markers (representing oncogenes), such as EGFR
[13], osteopontin (SPP1) [13,14], ERBB3 [15], MALAT1
[16], S100A2 [17-19], S100A6 [20], ABCC3 [21] and
ELN3 [24], as highly discriminative genes by the ECD is
quite encouraging (sheet S1.A in Additional file 1). This
identification suggests greatly enhances the clinical rele-
vance and potential of ECD signature, as the source
novel gene molecular classifiers of the AC and their bio-
markers. Some selected genes with high discriminative
ability, belonging to three cancer-relevant pathways,
such as ATP-binding cassette (ABC) family of genes
(ABCA4, ABCA8 [58]) were identified as prospective
gene markers of lung AC [21] other one (ABCB1,
ABCC3 and ABCF2) should be also under serious con-
sideration. Our microarray analysis results (sheet S1.a in
Additional file 1) and preliminary lung tissue array
study demonstrated that the ABC gene signature, con-
sisting of ABCA4 and ABCA8 together with ABCC3,
can discriminate lung AC vs AT and be considering as a
novel lung cancer diagnostic biomarker (not published).
We also identified a large number of cell adhesion and
cell communication pathway genes, such as CDH3,
SPP1, SPINK and CEACAM5 (sheet S1.A in Additional
file 1) that are highly up-regulated in all lung AC
t u m o u r s ,a n dh e n c ec o u l db ea s s o c i a t e dw i t ht h ee a r l y
metastasis of lung AC. Several tumour suppressor genes
are expressed at relatively low levels across all paired
samples studied. For instance, the transcription of the
TCF21 gene is strongly suppressed in AC vs. adjacent
lung tissue (sheet S-a in Additional file 1). TCF21 has
recently been reported as being essential for the differ-
entiation of epithelial cells adjacent to mesenchyme
[22,23]. TCF21 is considered to be a candidate tumour
suppressor at 6q23-q24 that is epigenetically inactivated
in lung, head and neck cancers [22,23]. TCF21 was also
mentioned as a promising cancer gene marker in a
report that focused on the differential methylation of a
short CpG-rich sequence [23]. In addition, we found
essential differences in the gene expression profiles of
key players in the focal adhesion pathway, such as FLNB
(sheet S1.A in Additional File 1).
Discriminative signature and meta-signatures contain
genes essential for oncogenesis and tumour progression
We demonstrated that the gene sets of ECD and Meta-
signature are significantly overlapped and both are
highly enriched with the terms of biological processes
and molecular functions which according to the
literature are essential in the lung cancer and other can-
cers. Unique features of AC Meta-signature show a
strong association with phosphate metabolic process,
intracellular signalling cascade, regulation of prolifera-
tion and apoptosis. Such functions in combination with
activity of the cancer-associated cell proliferative genes
are often considered as the aggressiveness score of a pri-
mary tumour. The genes and their products of this
unique subset might be used as a source of prognostic
and predictive biomarkers.
In light of our finding of the differences between com-
mon subset and unique AD discriminative signature, we
suggest that in addition to the common set of the core
proliferative genes, our ECD signature includes a subset
of genes encoding proteins that often undergo mutagen-
esis, provide a regulation of proliferation and the transi-
tion steps in the AC development. These genes and
their products might be considered as a source of early
and differential diagnostic biomarkers as well as the
prognostic biomarkers.
Feature selection paired design allows estimating the
gene marker space discriminating PT-AT and predicts
high plasticity of the transcritome in AC
Using 54 U133A microarray profiles of 27 paired sam-
ples of lung adenocarcinoma (AC) and adjacent lung tis-
sue, we identified the global reprogramming of the
transcriptional profile in human lung AC compared to
normal lung tissue. Through the mutual CN of expres-
sion data belonging to dependent paired samples and
using a separability score, calculated by the modified
Wilcoxon signed-rank test, the method provides an
essential improvement of the sensitivity of the feature
selection at the highest specificity (100%) in a compari-
son to the alternative methods. Our method reveals
expression shift of at least 2,428 genes discriminating
lung AC from adjacent normal lung tissues with ~100%
accuracy. Additionally, more than 2000 genes could dis-
criminate the lung AC tumours from the normal lung
tissues with ~93% accuracy.
Systematic structural and functional study of the pro-
tein peptides found in the common subset of the Meta-
signature and ECD signature (as well as SAM U95 sig-
nature and ECD signature) should be useful in our
understanding of the basic interactions of the tumour
with stroma, surrounding tissue, immune and endocrine
systems. Specifically, we suggest that immunity and sig-
nal peptides gene signatures (and their sub-networks)
could be used for early diagnostics of AC and for quan-
titative monitoring of the adjuvant therapy. Thus, we
could suggest that these genes may represent promising
targets for novel specific therapies.
Non-small cell lung cancer (NSCLC) can be classified
into the major subtypes, AC, and squamous cell
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58 human NSCLC specimens revealed large differences
between AC and SCC subtypes, with more than 1700
genes found to be differentially expressed [59]. The
assignment of these genes to biological processes
pointed to the deregulation of distinct sets of cell adhe-
sion molecules. In combination with our findings this
result reveals an extremely high dimensionality of the
potential biomarker space and plasticity of the transcrip-
tome in AC and SCC subtypes.
Further method improvement and validation studies
ECD provides superior selection in comparison to con-
ventional methods and can be widely used in different
applications. However, the selection and classification
performance and error estimation strongly depend on
the data set size and dimensionality of the co-variate
space. It is a challenging task to develop an exact model
of microarray data taking into account paired dependent
design and to compare the benefit of the model versus
non-paired design models. Several ways to treat paired
dependent data more efficiently in a parametric model-
ling framework have been proposed [60]. Using univari-
ate simulation models, the authors showed essential
misclassification of variance reduction in paired depen-
dent design model, even when the sample size is rela-
tively small. In the case of small sample size, it is
important to develop simulation models based on non-
parametric test (Methods, Figure 1) and to study (i) a
dependence of misclassification error from the sample
size, correlation patterns between paired features, (iii) a
role of dimensionality of the co-variate space and other
parameters of microarray data and clinical factors.
The thresholds of our feature selection procedure
could be fine-tuned and corrected (e.g. by relaxation of
the statistical criteria controlling FDR and modification
of the fold-change cut-off value). Despite the statistically
reasonable cut-off of p-value and the 100%-correct pre-
diction criteria, we found that a large proportion of the
lung cancer gene markers reported in the literature
were still filtered out (Methods). Some potentially
important gene markers, such as MYC and BRCA1 [3]
(one misclassification of 27 cases; Additional file 1) were
i g n o r e db yE C Dd u et oo u re x t r e m ec r i t e r i a .S i m i l a r l y ,
SCGB1A1, identified by The Cancer Gene Database as a
cancer-related gene [61], was also filtered out of our
gene set due to 100%- correct classification request of
our procedure. In addition, among the 26 gene markers
identified by Su et al. [37], the MWT identified only 7
genes as potential gene markers. Thus, the stringent
100%-correct classification criteria could be relaxed to
7% misclassification error rate, but to control the false
discovery rate we should increase the fold-change cut-
off value as well. For the MWT classifier we used 1.35
as the minimum value of fold-change for the 100%-cor-
rect classification criteria. We could decrease the cut-off
fold-change value down to 1.2, with 89%-correct classifi-
cation criteria. In these cases, the relaxed criteria pro-
vide an increment in the enrichment of the number of
differentially expressed genes and potential AC gene
markers included in our AC Meta-signature. We still
have significantly strong enrichment of the Meta-signa-
ture genes in extended gene set (Fisher exact two-tail p-
value=9.40E-127 and EF = 2.34). Such conditions allow
including the above mentioned genes, as well as many
other Meta-signature genes in our extended gene set.
More accurate explorations of the discriminative gene
signature method will allow development of more statis-
tically- and computationally- oriented feature selection
methods.
Another area for improvement could be the use of
datasets that are comprehensive and have more homo-
genous patient populations, such as pre-malignant
lesions, tissues at the early stage of tumour progression
and patients with different immune status.The human
lung tissue QRT-PCR array assay of 24 paired mRNA
samples of cancer and adjacent normal lung tissues was
used to validate two genes SPP1 and CENPA, which
perfectly discriminate lung AC from PT-ATs with con-
sistent fold-changes. These genes are completely discri-
minative and functionally essential and, thus, could be
considered for a simple and accurate diagnostic kit of
lung AC.
Many other genes and gene subsets which are
included in our ECD signature could be validated using
expression data from independent cohorts. For example,
immunity signature, defined in this study could be basic
set for development early AC diagnostic and prognostic
kit. These gene set accomplished 100% discrimination
ability of the pairs of normal and lung cancer tissue
samples, indicating discove r yo fm a n yn o v e lb i o m a r k e r s
with a significant potential for clinical applications.
Conclusions
In many medical applications, analysis of data taken
from paired samples of the same patient could increase
efficiency of the feature selection and reduce a risk of
misclassification. We develop a novel feature selection
method of microarray analysis of dependent paired sam-
ple design. The method identifies and selects highly dis-
criminative variables from high-dimensional data space
based on a statistical analysis of paired samples when
the number of samples is small. This method provides
superior selection in comparison to conventional meth-
ods and can be widely used in different applications.
ECD reveals ~2,300 patho-biologically essential genes
associated with the global transcriptional reprogram-
ming of human lung epithelium cells and lung AC
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spective AC biomarkers reflecting inherent disease com-
plexity and specifies the mechanisms of carcinogenesis
in the lung AC.
The extremely discriminative genes form four contrast
gene co-expression clusters with easy biological inter-
pretation. The 1
st most strong cluster represented by
lung AC mitotic/cell cycle up-regulated genes, 2-nd
cluster is represented by normal lung epithelial cells at
the strong suppression, 3-rd and 4-th clusters are repre-
sented by the genes involved in cell communication,
motility and the immune system.
We identified novel immune system signature of lung
A C ,w h i c hm i g h tb eu s e df o rf u t u r ed e v e l o p m e n to f
diagnostics, monitoring and prognosis of the patients
with AC.
17% of the proteins encoded by the discriminative
genes contain known mutagenesis sites. Similar fraction
of the known mutagenesis sites was found in the Meta-
signature set. We suggest that mutagenesis site-contain-
ing proteins found in both of our signatures could be
considered as casuistic players in pathobiology of AC
and prospective gene markers directly involved in mole-
cular mechanisms driving lung carcinogenesis and pro-
gression of AC.
A good agreement of selected genes with the set of
>1000 published potential molecular biomarkers and AC
signature genes was found. These genes as well as novel
genes of ECD-defined lung AC biomarker space could
be considered as the comprehensive source of novel bio-
markers. The human lung tissue QRT-PCR array assay
of 24 paired mRNA samples of cancer and adjacent nor-
mal lung tissues was used to validate two AC discrimi-
nating genes SPP1 and CENPA. Both of these genes
separate the normal and cancerous mRNA expression
signals in all 24 pairs studied. We suggest that these
genes could be considered as the prospective prognostic
and diagnostics biomarkers of the human lung AC.
Methods
Dataset
The present study used Su et al. [37] microarray data
downloaded from NCBI’s GEO database (http://www.
ncbi.nlm.nih.gov/geo/), under the GEO accession num-
ber GSE7670. The lung tissue samples were obtained
during the lung cancer patients’ surgery. The authors
selected adjacent normal-tumour matched lung cancer
pair samples for RNA extraction and hybridization of
mRNA to Affymetrix U133A microarray platform
(22,283 probe sets) based on the manufacturer’ss t a n -
dard protocol. In total, 66 microarray samples were
available (which also included expression measurements
on several lung cancer cell lines, normal lung tissue and
mixed tissues). We used 54 pair-wise tissue samples,
selected from 27 patients.
The microarray hybridization signal intensity values of
the 22,283 U133A probe sets were MAS5.0 calibrated, and
the values were scaled by adjusting the mean signal inten-
sity values to a target value of log500. For the present
study, we used non-log transformed data (log-transformed
data provided slightly worse results; data not presented).
General model of paired dependence test
The workflow of our discriminative feature selection
method is given in Figure 1. Briefly, a feature (probeset
or associated RefSeq gene) j, j (j =1 ,…, M), measured
in the cancer (class1 or Y) and surrounding tissue sam-
ples (class2 or X) of N patients, i =1 ,…, N, is discrimi-
native if there is a significant difference between the
expression levels of the two classes. Let Iij
Y denote the
microarray expression signal of patient i, probeset j and
class Y. Similarly denote as Iij
X the paired data of class
X. We assume no missing data for each pair pair
II ij
Y
ij
X , () . The paired dependence test compares the
repeated measurements within subjects, rather than
across subjects, and in our case has greater power than
an unpaired test.
In a classical univariate paired difference analysis, we
would first subtract the non-disease value from the dis-
ease value for each measured variable of the same sub-
ject, then compare these distribution of the differences
around zero. Mathematically, let DII ij ij
Y
ij
X =− and D j
denote the average difference of probeset j across the N
patients.
The mean difference between the groups does not
depend on whether we organize the data as pairs. The
mean difference is the same for the paired and unpaired
statistics but their statistical significance levels can be
very different, because of the estimation of the variance
component. Below we show that the variance of Dj in
paired samples is lower because there is positive correla-
tion within each dependent pair.
A random effects model for paired testing
The following statistical model is useful for understand-
ing the paired difference test:
Yij = μj + ai + εij
where ai is a random effect that is shared between the
two values in the pair, and εij is a random noise term
that is independent across all data points. The constant
values μ1, μ2 are the expected values of the two mea-
surements being compared, and the test interest is in δ
= μ2 − μ1.
In this model, the ai capture “stable confounders” that
have the same effect on the “normal” tissue and “abnor-
mal” tissue measurements. In unpaired data analysis the
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In paired data the within-pairs covariance is Cov(a)>0
which decreases the variance of δ differences and leads
to better performance.
Modified Wilcoxon test (MWT)
MWT is a simple non-parametric separability test of
paired data, which can be used to select the highly dis-
criminative features (gene markers).
Obtaining a sufficiently large number of sample pairs
in clinical microarray studies is a very difficult task.
Usually, the number of paired samples is smaller than
that in studies of independent samples. To cope with
these constraints, a nonparametric approach is appropri-
ate. Specifically, the Wilcoxon signed (WT) rank test
[62] can be used. This test uses the model
De  N   M ij i jj ij =+ = = θ ,, , ;, , , , , 11 2 3  (1)
where Dij has been defined above θ is the unknown
‘disease effect’,a n de ij are random errors, which are
assumed to be mutually independent and symmetric
about zero.
To test the null hypothesis of no disease effect is
equivalent to test:
H j 0 0 : θ= (2)
O u rm o d i f i c a t i o no ft h em o d e lo fW T( M W T )
involves the Cross Normalization step and the Wilcoxon
sign rank test as follows:
1: Calculate the class average across samples:
DII i j ij ij
Y
ij
X =− = = (, , ; , , ) 11  NM .
2: Cross-normalize the average of the opposite class
dd II I II I ij Y
X
ij
X
j
Y
ij X
Y
ij
Y
j
X
,, =− =−  and  (3)
where I j
Y and I j
X are the average expression levels
for probeset j across N patients at classes Y and X,
respectively.
3: Calculate differences between cross-normalized vec-
tors for each sample pair:
dI I ji j Y
X
ij X
Y =− dd ,, (4)
4: Calculate the absolute value of the differences
obtained from Step 3.
5: Rank the differences obtained from Step 4 (R
-/+).
6: Obtain the sum of the total ranks of each individual
sign (+ and -).
7: Calculate the Z-value using the smaller value R
-/+
(Step 6) with the following formula:
Z
R
=
−
−+ /
,
m
s
(5)
where:
ms =
×+
=
×+ × + NN NN N ()
,
() ( ) 1
4
12 1
24
(6)
And N is the total number of paired samples.
8: Introduce the correction factor of N
N
− 2 into the
Z-value:
Z
RN
N
=
−
×
−
−+ /
.
m
s
2 (7)
9 :C a l c u l a t et h ep - v a l u ef r o mt h eZ - t a b l e
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− 1
2
2
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p
[62] and disregard data that are less
than the defined threshold of 0.05.
10: Calculate the separation error of each feature
(gene expression signal):
Let t
+VE denote the number of patients that have a
positive dj.
Let t
-VE denote the number of patients that have a
negative dj
Calculate the percentage of classification errors, by
using the smaller value of t
+VE and t
-VE over N ( t
N
VE +
or t
N
VE −
).
11: Select only the probe-sets with the number of clas-
sification errors equal to zero.
Notice: Steps 3 – 7 are used by the original Wilcoxon
signed-rank test.
Note using CN procedure, our paired dependence
analysis (3) combines the properties of the parametric
symmetry (zero mean the differences) test and the non-
parametric (zero rank the differences) symmetry test.
The sign symmetry test
A sign test could be used to estimate the probability of
misclassifications error in paired sample experimental
design (tumour vs. normal tissues from the same organ
of a patient). For each microarray expression signal i,
given the gene expression int e n s i t yv a l u e so f2 7i n d e -
pendent patients measured in two conditions, we can
estimate the probability of observing less than s patients’
misclassifications. This probability of observing an event
that is more extreme than s (p-value) and can be esti-
mated by the Binomial distribution. Assuming that the
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the probability of misclassification is the following:
Pr( ; , . ) ks N p
N
k
pp
N
k
p
ks
N
kNk
k
n
N ≥= ==
⎛
⎝
⎜
⎞
⎠
⎟ =
⎛
⎝
⎜
⎞
⎠
⎟
=
−
= ∑∑ 27 0 5
25
For example the probability of at most two misclassifi-
cations in 27 paired samples is calculated as:
P value k −= ≥= = = ×
− Pr( ; , . ) . , 25 27 0 5 2 82 10
6 Np
which after Bonferroni correction on the number of
U133A probe sets becomes adjusted p-value = 0.062.
A bootstrap test of stochastic equality of two populations
Bootstrapping testing [63] was used to calculate the sig-
nificance of each Affymetrix U133A probe set hybridiza-
tion signal. To calculate the bootstrap P value the
samples were randomly resampled (with replacement)
9,999 times, MWT was run and Pboot was estimated.
The P values of interest is Bootstrap P = (number of
times Pboot < Ptest)/9999. Only the signals with boot-
strap p-values less than 0.05 were considered.
Programming based on MWT
A program in C++ language was written for the MWT
method to process the microarray Affymetrix data sets.
The data, when processed through the program, generate
an N x M table of cross-normalized data, where M is the
number of the Affymetrix ID and N is the number of the
Patient’s ID. Another N x M table contains 1-s and 0-s,
where 1 represents positive signs and 0 represents nega-
tive signs of gene expression in the pair. This indicates
the relative down- or up- regulation of a given hybridisa-
tion signal (corresponding to the expression level of the
gene transcript) for a given object of the class Y (cancer
tissue) in comparison to the paired object of the class X
(normal tissue). Finally, the M U133A probe set IDs
(representing the M columns of the table) are sorted
based on the MWT p-values, and the total number of 1-s
(and percentage) for each microarray probe set ID is
tabulated. The program also calculates the ratio of the
average expression signals of Class 2 to Class 1.
Hypergeometric P-Value
Hypergeometric function (Fisher exact) test [54,62] is
use to assess the significance of the overlapping region
in the Venn diagram. The terms we use are as follows:
k: Number of elements in the overlapped region of the
Venn diagram
n: Total number of elements present in group 1
m: Total number of elements present in group 2
N: Total number of elements present in both groups.
To find the probability that k or more elements inter-
sect subsets of n and m members at random (or the p-
value for overlap of k) in a universe set of size N, we sum-
mon over the right tail of a hypergeometric distribution:
Pr(k ≥ l;n , m, N): =p-value
pv a l u e k n m N
Nm
nl
m
l
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n
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This is a one-sided test where the p-values correspond
to over-represented lists of elements (genes) in the
intersection region of the Venn diagrams. In the case of
Refseq genes non-redundantly presented on U133A
microarray N equals 13074.
Student’s t-test and Wilcoxon test with FDR correction
The standard Student’s t-test for paired data and the
non-parametric Wilcoxon signed-rank test for paired
data, implemented in the R statistical package as the ‘t.
test’ and ‘wilcox.test’ functions, were used to compare
the expression levels in pairs of normal and tumour
samples. The resulting P-values were corrected with the
FDR values using p-value adjustment module ‘p.adjust’,
implemented in the R statistical package. The ensuing
FDR values were used to rank the genes, and the desired
number of genes was then selected for use.
EDGE analysis
An optimal discovery procedure (ODP) method, imple-
mented in the Extraction of Differential Gene Expres-
sion (EDGE) [64] program, was used to assess the
significance of the differential expression of the genes
between paired tumour and normal tissue samples of
t h es a m ep a t i e n t s .T h ep a i r e d microarray information
was incorporated into EDGE, using the ‘MATCHED
DESIGN SETTINGS’ option. The false discovery rate
(FDR) for selected genes was monitored and controlled
by calculating the q-value. By default, for the present
dataset, genes with a q value <0.00021 were considered
as significantly differentially expressed genes between
the comparison groups by EDGE. However, to allow
comparison with other methods, the genes were rank
ordered using the FDR values, and the desired numbers
of genes were then selected for further analysis.
PAM and SAM analysis
Initially, we ran the PAM algorithm [51] with all 22,283
U133A probe sets as input in the tumour to normal
sample comparisons, and acquired an extreme discrimi-
nation set of 77 probe sets, which gave the lowest
Toh et al. BMC Genomics 2011, 12(Suppl 3):S24
http://www.biomedcentral.com/1471-2164/12/S3/S24
Page 21 of 24misclassification (error) rate: 0 of 27 for normal and 1 of
27 for tumour predictions. The paired array information
was incorporated into PAM by using identical sample
IDs for the paired normal-tumour samples. SAM analy-
sis [50] was also used for selection of differentially
expressed gene signals.
Hierarchical cluster analysis
Hierarchical cluster analysis was performed with XClus-
ter [65], using both Euclidian- and centred Pearson cor-
relation coefficient-distance metrics and average linkage
to measure the cluster distances during partitioning.
Two-way clustering was employed to group both micro-
arrays and samples on one axis and the probe sets on
the other axis. The resulting clustered structures were
displayed as heatmaps, using the Java Tree View soft-
ware [66].
GO analysis
Diavid Bioinformatics [67], ClueGO [68], Panther Bioin-
formatics [69]and GeneGo(Metacore) [70]tools were
used to evaluate the Gene Ontology terms enrichment
in gene/protein groups.
Tissue scan qRT-PCR array
Primers were designed for validating 2 discriminative
genes which perfectly classify lung tumours from sur-
rounding normal tissues (obtained based on computa-
tional methods). Relative levels of mRNA of genes
selected for validation were quantified using Tissue scan
panel HLRT-02 which includes 24 lung cancer cDNA
samples matched in pairs with surrounding lung (nor-
mal) cDNA samples. This panel was provided by the
OriGene Technologies, Rockville MD (manufacture).
The panel contains pre-normalized 48 cDNA samples
with various subtypes of lung cancer with information
regarding TNM, tumour size, tumor type, stage, age and
other clinical information. qRT-PCR experiments were
carried out on Applied Biosystems 7500 Real Time PCR
machine. The normal to tumour Ct-values of each gene
were obtained and relatively quantified using ΔΔCt ana-
lysis [71]. Primers were designed for SPP1 (For- CTC
CAT TGA CTC GAA CGA CTC and REV- CAG GTC
TGC GAA ACT TCT TAG AT ) and CENPA (For-
AGC ACA CAC CTC TTG ATA AGG A and REV-
CAC ACC ACG AGT GAA TTT AAC AC ) along with
control Actin-B (commercially provided).
Additional material
Additional file 1: Table S1. Master table annotated with gene symbols
with gene symbols from Lung AC meta gene signatures, default and
relaxed lung AC gene signatures and signatures derived by other
methods cited in the literature.A: Characteristics of the data set and final
results; B: Read me File C: Summary statistics. D: AC signature derived by
SAM software from U95A data. S1e: Tables of the 604-gene PT-AT
consensus signature, the results of GO analysis, the immunity and cell
cycle gene signatures discriminating AC from normal lung tissues.
Additional file 2: Table S2. Distribution of the number of false
classifications of the 27 paired samples. Comparison of the classification
accuracy of the extremely discriminative 2,829 probe sets (ECD) with the
top-level 2,829 probe sets identified by the standard Wilcoxon sign
ranked test (WT), EDGE, PAM, and Student’s t-test. (ECD signature was
selected using MWT on cross-normalized signal intensities with 100%
accuracy criteria and a bootstrap p-value cut-off<0.05). While the ECD
classifier was derived using the cross-normalized dataset as input, the
classifiers derived using PAM, EDGE, WT and t-test used the original
MAS5-normalized data as input. However, the classification accuracy, in
terms of the number of probe sets with 2 or more anomalous fold-
changes, was estimated using the MAS5-normalized dataset.
Additional file 3: Comparison of different feature selection
methods. Analysis of discriminative ability using the original MAS5
normalized data The two-way hierarchical cluster analysis of the 2,829
probe sets and the 27 pairs of normal-lung AC samples demonstrates
the ability of the selected methods to separate lung AC from normal
samples (Supplementary figures S1-S4). All of the methods, with the
exception of the t-test and the Limma paired test, produced a near-
perfect separation of the two classes, however, ECD provides more
biologically reasonable grouping of the genes (see Results). Figure S1.
Two-way hierarchical cluster analysis of the MAS5-normalized expression
values of 2,829 probe sets identified by the standard Wilcoxon test.
Figure S2. Two-way hierarchical cluster analysis of the cross-normalized
expression values of the 2,829 probe sets identified by EDGE. Figure S3.
Two-way hierarchical cluster analyses of (A) the MAS-normalized
expression values and (B) the cross-normalized expression values of 2,829
probe sets identified using the Student’s t-test. Figure S4. Two-way
hierarchical cluster analyses of (A) the MAS-normalized expression values
and (B) the cross-normalized expression values of 2,829 probe sets
identified using the Limma paired t-test (Smyth, G. K., 2005).
Additional file 4: Table S3. Meta-gene signatures associated with Lung
AC, curated from the literature with the corresponding references.
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